Who Can Legally Prescribe Zepbound and Compounded Tirzepatide: The State-by-State Credentialing Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (NP), and physician assistants (PA) can all prescribe Zepbound, but prescribing authority varies by state and practice setting
• Telehealth prescribers must hold an active license in the state where the patient physically receives care, not where the provider practices
• Compounded tirzepatide requires the same prescribing authority as brand-name Zepbound but follows different pharmacy dispensing rules
• 23 states grant full practice authority to nurse practitioners, allowing them to prescribe without physician supervision; 27 states require collaborative agreements or supervision

Direct answer (40-60 words)

Zepbound can be prescribed by medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (NP), and physician assistants (PA) who hold valid state medical licenses and DEA registration. Prescribing authority for NPs and PAs varies by state. Telehealth providers must be licensed in the patient's state. Naturopaths, pharmacists, and registered dietitians cannot prescribe Zepbound.

Table of contents

1. The credential hierarchy: who has prescribing authority
2. State-by-state variation in NP and PA prescribing rules
3. The telehealth licensing requirement most patients misunderstand
4. What most articles get wrong about "supervising physicians"
5. DEA registration and controlled substance scheduling (why it matters for GLP-1s)
6. Compounded tirzepatide prescribing: same rules, different pharmacy pathway
7. The FormBlends provider credentialing pattern
8. Specialists vs primary care: does it matter who writes the prescription?
9. When your current provider can't or won't prescribe
10. The three-question provider qualification checklist
11. FAQ
12. Footer disclaimers

The credential hierarchy: who has prescribing authority

The legal authority to prescribe Zepbound flows from three sources: professional degree, state medical board licensure, and DEA registration. All three must align.

Tier 1: Physicians (MD and DO)

Medical doctors and doctors of osteopathic medicine hold unrestricted prescribing authority in all 50 states. An MD or DO licensed in any state can prescribe any FDA-approved medication within their scope of practice, including Zepbound, without supervision or collaborative agreements. This is the broadest prescribing authority available.

Tier 2: Advanced practice providers (NP and PA)

Nurse practitioners and physician assistants have prescribing authority that varies significantly by state. In 23 states plus Washington D.C., NPs have full practice authority and can prescribe independently. In the remaining 27 states, NPs require a collaborative agreement with a physician or direct supervision.

Physician assistants operate under a supervising physician in all states, but the definition of "supervision" ranges from same-building presence (rare) to quarterly chart review (common). The supervising physician does not need to specialize in obesity medicine or endocrinology.

Tier 3: Limited prescribers (state-dependent)

Some states grant limited prescribing authority to:

• Naturopathic doctors (ND) in states where naturopathy is a regulated profession (currently 26 states, but formulary restrictions often exclude GLP-1 medications)
• Optometrists (OD) for medications related to eye conditions only
• Podiatrists (DPM) for medications related to foot and ankle conditions only
• Clinical pharmacists under collaborative practice agreements in 13 states (formulary varies; most exclude weight-loss medications)

No prescribing authority:

• Registered nurses (RN, BSN)
• Licensed practical nurses (LPN)
• Registered dietitians (RD, RDN)
• Health coaches
• Pharmacists without collaborative practice agreements

The credential after the name matters. "Dr." alone doesn't indicate prescribing authority. A PhD nutritionist cannot prescribe Zepbound. A naturopathic doctor in California can prescribe some medications but not in Tennessee, where naturopathy is unregulated.

State-by-state variation in NP and PA prescribing rules

The American Association of Nurse Practitioners tracks three categories of state practice authority for NPs:

Full practice authority (23 states + D.C.): Alaska, Arizona, Colorado, Connecticut, Hawaii, Idaho, Iowa, Maine, Maryland, Massachusetts, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Dakota, Oregon, Rhode Island, South Dakota, Vermont, Washington, Wyoming, and Washington D.C.

In these states, NPs can evaluate patients, order tests, diagnose conditions, and prescribe medications including Zepbound without physician oversight.

Reduced practice authority (15 states): Arkansas, Delaware, Illinois, Kansas, Kentucky, Louisiana, Mississippi, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Utah, West Virginia, Wisconsin.

NPs can prescribe but require a collaborative agreement with a physician. The agreement typically specifies the scope of prescribing authority and may require periodic chart review. The collaborating physician does not need to be on-site.

Restricted practice authority (12 states): Alabama, California, Florida, Georgia, Indiana, Michigan, Missouri, North Carolina, South Carolina, Tennessee, Texas, Virginia.

NPs must work under direct physician supervision. Prescriptions may require co-signature or protocol approval. The definition of "supervision" varies; in some states it means same-building presence, in others it means availability by phone.

Physician assistants: All 50 states require PAs to practice under a supervising physician, but supervision models vary. The supervising physician does not need to be present during patient encounters in 48 states. Chart review frequency ranges from real-time to quarterly.

The practical impact: if you're working with a telehealth platform that employs NPs, the NP must hold a license in a full-practice-authority state OR the platform must maintain collaborative agreements with physicians in every restricted-authority state where patients are located. Most platforms choose the former model and limit service to full-practice-authority states.

The telehealth licensing requirement most patients misunderstand

The most common misconception about telehealth prescribing: "My provider is licensed in New York, so they can prescribe to me anywhere."

Wrong. The governing rule is the Ryan Haight Act (2008) and subsequent DEA guidance: a prescriber must hold an active, unrestricted medical license in the state where the patient is physically located at the time of the consultation AND where the patient will receive the medication.

Example scenarios:

• You live in Texas. You consult with a California-licensed provider via telehealth. The provider cannot prescribe to you unless they also hold a Texas medical license.
• You live in Florida but are temporarily in Georgia. A Florida-licensed provider can prescribe to you only if you return to Florida to receive the medication. If you want it shipped to Georgia, the provider needs a Georgia license.
• You split time between two states. The provider must hold licenses in both states to prescribe continuously.

The license requirement applies to the patient's location, not the provider's. A New York-based provider can prescribe to a Texas patient if the provider holds a Texas medical license, even if the provider never physically enters Texas.

The COVID-era exception that expired: During the federal public health emergency (March 2020 to May 2023), the DEA waived the in-state license requirement for telehealth prescribing. Providers could prescribe across state lines using their home-state license. That waiver ended May 11, 2023. Any platform still operating under the old rules is non-compliant.

How multi-state platforms work: Platforms like FormBlends maintain provider networks licensed in all 50 states. When you create an account, the platform routes you to a provider licensed in your state. The provider you consult may be physically located anywhere, but they hold an active license where you are.

The license database is public. You can verify any provider's license status at the state medical board website. If a telehealth platform won't tell you which state their provider is licensed in, that's a red flag.

What most articles get wrong about "supervising physicians"

The phrase "supervising physician" appears in nearly every article about NP and PA prescribing, but most articles misrepresent what supervision actually means in 2026.

The misconception: The supervising physician reviews every prescription, meets with the NP or PA daily, and is personally responsible for every clinical decision.

The reality: In 48 states, "supervision" for PAs and "collaboration" for NPs in reduced-authority states means the physician is available for consultation and conducts periodic chart review. The frequency is typically quarterly, not daily. The physician does not co-sign individual prescriptions in most states.

The supervising physician's role is quality oversight, not micromanagement. A PA working in a telehealth weight-loss clinic might see 30 patients per day. The supervising physician reviews a sample of charts every 90 days, checks for prescribing patterns outside clinical guidelines, and is available by phone for complex cases. The PA makes the day-to-day prescribing decisions independently.

Why this matters for patients: If you're working with a PA or NP in a reduced-authority state and you ask to speak with the "supervising physician," you're asking for an escalation that's rarely necessary. The NP or PA is the appropriate clinical contact for routine questions about Zepbound. The supervising physician steps in for complications, adverse events, or cases outside the NP's scope.

The competence of the prescriber does not correlate with credential type. An NP who has managed 500 tirzepatide titrations has more relevant experience than an MD who prescribed their first GLP-1 last month. The credential determines legal authority; experience determines clinical judgment.

The exception: In restricted-authority states (Alabama, California, Florida, Georgia, Indiana, Michigan, Missouri, North Carolina, South Carolina, Tennessee, Texas, Virginia), the supervising physician may be required to co-sign prescriptions or maintain same-building presence. This is state-specific. If you're in one of these states, ask the platform how supervision is structured.

DEA registration and controlled substance scheduling (why it matters for GLP-1s)

Every prescriber who writes prescriptions must hold a Drug Enforcement Administration (DEA) registration number. The DEA number is tied to the prescriber's license and the physical location where they practice.

Zepbound and other GLP-1 medications are not controlled substances. They are not scheduled under the Controlled Substances Act. A provider does not need a DEA number specifically to prescribe Zepbound.

So why does DEA registration matter? Because most state medical boards require active DEA registration as a condition of maintaining prescribing privileges, even for non-controlled medications. A provider whose DEA registration has lapsed or been revoked typically loses all prescribing authority, not just controlled substance authority.

When you verify a provider's credentials, check:

1. Active state medical license (state medical board website)
2. Active DEA registration (DEA practitioner lookup tool)
3. No disciplinary actions or restrictions (state medical board public records)

The DEA number format is two letters followed by seven digits. The first letter indicates credential type:

• A or B: physician, dentist, veterinarian, podiatrist
• F: mid-level practitioner (NP, PA, etc.)
• M: mid-level practitioner (alternate format)

If a telehealth platform won't provide the prescriber's DEA number or state license number before the consultation, that's a compliance red flag.

The compounding pharmacy question: Some patients ask whether DEA registration matters differently for compounded tirzepatide vs brand-name Zepbound. It doesn't. The prescribing authority is identical. The difference is on the pharmacy side: compounding pharmacies must meet additional state and federal regulations (FDA 503A or 503B registration), but the prescriber's credential requirements are the same.

Compounded tirzepatide prescribing: same rules, different pharmacy pathway

Compounded tirzepatide and brand-name Zepbound require identical prescribing authority. An MD, DO, NP, or PA licensed in your state can prescribe either one. The credential requirements do not change.

The difference is the pharmacy pathway:

Brand-name Zepbound:

• Manufactured by Eli Lilly
• FDA-approved
• Dispensed by retail or mail-order pharmacies
• Covered by some insurance plans (prior authorization usually required)
• Prescription sent via e-prescribe to a pharmacy of your choice

Compounded tirzepatide:

• Prepared by a 503A or 503B compounding pharmacy
• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• Not covered by insurance
• Prescription sent to a specific compounding pharmacy, not a retail chain
• Legal to compound only during periods of FDA-declared shortage OR for patient-specific medical need (allergy to inactive ingredients, dose not commercially available, etc.)

The prescriber's decision to write for brand vs compounded is a clinical and logistical choice, not a credential issue. The same provider can prescribe both. Many telehealth platforms work exclusively with compounding pharmacies because the economics are simpler (no insurance, no prior authorization, predictable cash pricing).

The 503A vs 503B distinction: 503A pharmacies compound patient-specific prescriptions in response to individual orders. 503B outsourcing facilities can compound larger batches and distribute to healthcare facilities. For patient-direct telehealth, 503A is the standard model. The prescriber does not need to specify 503A vs 503B on the prescription; the pharmacy's registration determines which pathway applies.

State-specific compounding restrictions: Some states impose additional restrictions on compounded weight-loss medications. As of April 2026, no state has banned compounded tirzepatide outright, but several states (Louisiana, Mississippi, Arkansas) require additional documentation of medical necessity. If you're in one of these states, the prescriber may need to include a diagnosis code and a statement that brand-name medication is not appropriate.

The FormBlends provider credentialing pattern

Across the FormBlends provider network, we see a consistent credentialing pattern that reflects how telehealth weight-loss platforms structure provider teams in 2026.

Primary prescribers: 68% nurse practitioners, 22% physician assistants, 10% physicians (MD/DO). The NP-heavy model reflects two factors: NPs are trained specifically in chronic disease management and health promotion (the core of weight-loss medicine), and NPs in full-practice-authority states can operate independently without physician co-signature overhead.

Geographic distribution: Providers are licensed in all 50 states, but the highest concentration is in full-practice-authority states (Colorado, Arizona, Montana, Washington) where NPs can prescribe without collaborative agreements. This allows the platform to serve patients nationwide by routing consultations to appropriately licensed providers.

Supervision structure for PAs and NPs in reduced-authority states: The platform maintains collaborative agreements with board-certified physicians (typically family medicine or internal medicine) who conduct quarterly chart reviews. The collaborating physician is available for escalation but does not review routine refill requests or dose adjustments.

Credential verification: Every provider undergoes primary source verification of medical license, DEA registration, malpractice insurance, and board certification (where applicable). Licenses are re-verified every 90 days using automated monitoring of state medical board databases.

Continuing education: Providers complete obesity medicine-specific CME annually, including GLP-1 pharmacology, adverse event management, and contraindication screening. This is above the state-required CME minimums.

The pattern we see most often: patients initially expect to work with a physician and are surprised to be matched with an NP or PA. After the first consultation, credential type stops mattering. The relevant question is whether the provider has managed hundreds of GLP-1 titrations, not whether they have "MD" after their name.

The credential that matters most is not the degree but the license status. An MD whose license is under investigation cannot prescribe. An NP with an active, unrestricted license in a full-practice-authority state has broader prescribing authority than an MD whose license is restricted to supervised practice.

Specialists vs primary care: does it matter who writes the prescription?

Zepbound and compounded tirzepatide are most commonly prescribed by:

• Family medicine physicians
• Internal medicine physicians
• Nurse practitioners (family or adult-gerontology)
• Physician assistants
• Endocrinologists (for patients with diabetes; less common for obesity-only)
• Bariatric medicine specialists (board certification available through ABOM)

Does the specialty matter? For straightforward weight loss in otherwise healthy adults, no. A family medicine NP with 500 GLP-1 titrations under their belt has more relevant experience than an endocrinologist who primarily manages thyroid disease.

Specialty matters when:

• You have complex comorbidities (uncontrolled diabetes, chronic kidney disease, heart failure, history of pancreatitis)
• You've failed multiple prior weight-loss medications
• You're considering combination therapy (tirzepatide plus metformin, topiramate, naltrexone, etc.)
• You have a history of eating disorders or psychiatric contraindications

In these cases, an endocrinologist or bariatric medicine specialist brings additional depth. But for the 80% of patients who are metabolically healthy aside from elevated BMI, the prescriber's experience with GLP-1 medications matters more than their specialty.

Board certification: Physicians can be board-certified by the American Board of Obesity Medicine (ABOM), which requires passing a comprehensive exam and maintaining CME in obesity medicine. As of 2026, about 7,000 physicians hold ABOM certification. NPs and PAs can earn the Certified Obesity Care Provider (COCP) credential through the Obesity Medicine Association.

These certifications signal focused training but are not required to prescribe Zepbound. Most telehealth providers do not hold obesity medicine certification. The certification is more common in brick-and-mortar weight-loss clinics.

The referral question: If your primary care provider refers you to a specialist for Zepbound, it usually means one of two things: (1) your PCP is uncomfortable managing GLP-1 medications and wants a specialist to initiate treatment, or (2) you have comorbidities that warrant specialist oversight. Once treatment is stable, many specialists refer back to primary care for ongoing management.

When your current provider can't or won't prescribe

Three common scenarios:

Scenario 1: Your provider doesn't prescribe GLP-1 medications for weight loss.

Some primary care providers limit their scope to acute care and chronic disease management (hypertension, diabetes, cholesterol) and refer out for weight-loss medication. This is a scope-of-practice choice, not a credential limitation. The provider is legally allowed to prescribe but chooses not to.

Your options:

• Ask for a referral to a provider who does prescribe GLP-1s
• Use a telehealth platform that specializes in weight-loss medication
• Find a bariatric medicine clinic in your area

Scenario 2: Your provider will prescribe brand-name Zepbound but not compounded tirzepatide.

This is common. Many providers are uncomfortable prescribing compounded medications because compounded drugs have not undergone FDA approval. The provider may also be unfamiliar with the 503A/503B regulatory framework or concerned about liability.

Your options:

• Accept brand-name Zepbound and work through insurance prior authorization
• Use a telehealth platform that works with compounding pharmacies
• Educate your provider on FDA's compounding guidance (though this rarely changes minds)

Scenario 3: Your insurance requires prior authorization and your provider won't complete the paperwork.

Prior authorization for Zepbound typically requires:

• Documentation of BMI ≥30 or BMI ≥27 with weight-related comorbidity
• Documentation of prior weight-loss attempts (diet, exercise, behavioral therapy)
• Sometimes documentation of failed trials of other weight-loss medications

The paperwork burden is significant (15 to 30 minutes per prior auth). Some providers, especially in high-volume practices, decline to complete prior authorizations for weight-loss medications because the reimbursement doesn't justify the time.

Your options:

• Offer to complete the patient portions of the prior auth forms yourself
• Ask the office staff (not the provider) to handle the prior auth
• Switch to a cash-pay model (brand-name Zepbound or compounded tirzepatide)
• Use a telehealth platform where prior auth is not required

The frustrating reality: the provider who knows you best may not be the provider most willing to prescribe GLP-1 medications. Telehealth platforms exist specifically to fill this gap.

The three-question provider qualification checklist

Before starting Zepbound or compounded tirzepatide with any provider (in-person or telehealth), ask three questions:

1. Are you licensed in the state where I live?

The answer must be yes. If the provider hedges or says "we're working on getting licensed in your state," walk away. Prescribing across state lines without an in-state license is illegal under the Ryan Haight Act.

You can verify the answer yourself at your state medical board website. Every state maintains a public license lookup tool. Search by the provider's name. The license must be active and unrestricted.

2. How many patients have you started on tirzepatide or semaglutide in the past 12 months?

You're looking for a number above 50. Below 50 suggests the provider is still building experience. Above 200 suggests the provider has seen the full range of common side effects and knows how to manage them.

If the provider says "I don't track that" or refuses to answer, that's a yellow flag. Experienced providers know their volume.

3. What's your protocol for managing severe nausea or vomiting that doesn't resolve in 48 hours?

The answer should include:

• Dose reduction or temporary hold
• Anti-nausea medication options (ondansetron, metoclopramide, promethazine)
• Hydration guidance
• Clear criteria for when to seek emergency care (signs of pancreatitis, dehydration, gastroparesis)

If the provider says "that's rare, it probably won't happen to you," that's a red flag. Severe nausea happens in about 8% of tirzepatide patients (Jastreboff et al., NEJM 2022). An experienced provider has a management protocol ready.

Bonus question for telehealth platforms: How do I reach someone if I have a side effect after business hours?

The answer should be a 24/7 nurse line, an on-call provider, or a clear escalation pathway. "Send us a message and we'll respond within 24 hours" is not acceptable for acute side effects.

The decision tree: finding the right prescriber for your situation

Start here: Do you have a primary care provider you see regularly?

Yes → Does your PCP prescribe GLP-1 medications for weight loss?

• Yes: Start there. Your PCP knows your medical history and can integrate GLP-1 therapy into your overall care plan. Ask about brand vs compounded options and insurance coverage.
• No: Ask for a referral to a provider who does, OR use a telehealth platform if you prefer not to add another in-person appointment.

No → Do you have complex medical conditions (uncontrolled diabetes, kidney disease, heart failure, history of pancreatitis, eating disorder history)?

• Yes: See an endocrinologist or bariatric medicine specialist for initial evaluation. Telehealth platforms are not ideal for complex cases.
• No: Telehealth platform is appropriate. Choose one that employs providers licensed in your state.

Insurance coverage question: Will you use insurance or pay cash?

Insurance:

• Brand-name Zepbound only (compounded medications are not covered)
• Requires prior authorization (expect 1 to 3 week delay)
• Copay ranges from $25 to $1,400/month depending on plan
• Must use a provider who accepts your insurance OR is willing to complete prior auth for an out-of-network claim

Cash:

• Brand-name Zepbound: $1,060/month list price (Lilly savings card may reduce to $550/month if eligible)
• Compounded tirzepatide: $250 to $450/month depending on dose and pharmacy
• No prior authorization required
• Telehealth platforms typically offer cash-only compounded options

Geographic constraint: Are you in a full-practice-authority state for NPs (see list in section 2)?

Yes: You have access to the widest range of telehealth platforms. NPs can prescribe independently.

No: Verify that the telehealth platform maintains collaborative agreements with physicians in your state. Some platforms limit service to full-practice-authority states.

FAQ

Can a nurse practitioner prescribe Zepbound? Yes. Nurse practitioners can prescribe Zepbound in all 50 states, but prescribing authority varies. In 23 states plus D.C., NPs have full independent prescribing authority. In 27 states, NPs require a collaborative agreement with a physician or supervision. The NP must hold an active license in the state where you live.

Can a physician assistant prescribe Zepbound? Yes. Physician assistants can prescribe Zepbound in all 50 states under the supervision of a licensed physician. The supervising physician does not need to be present during your consultation and typically conducts periodic chart review rather than reviewing every prescription.

Do I need to see an endocrinologist to get Zepbound? No. Zepbound can be prescribed by family medicine physicians, internal medicine physicians, nurse practitioners, and physician assistants. Endocrinologists are appropriate for complex cases (uncontrolled diabetes, kidney disease, history of pancreatitis) but are not required for straightforward weight loss.

Can my primary care doctor prescribe Zepbound? If your primary care doctor is an MD, DO, NP, or PA with an active license and DEA registration, yes. Whether they will prescribe depends on their comfort level with GLP-1 medications and their practice policies. Many primary care providers refer to specialists or telehealth platforms for weight-loss medication management.

Can a telehealth provider prescribe Zepbound if they're in a different state? Only if the provider holds an active medical license in the state where you physically live. A California-licensed provider cannot prescribe to a Texas patient unless the provider also holds a Texas license. This is a federal requirement under the Ryan Haight Act.

What's the difference between a prescriber for brand-name Zepbound vs compounded tirzepatide? There is no difference in prescribing authority. The same credentials (MD, DO, NP, PA) are required for both. The difference is the pharmacy pathway: brand-name goes through retail pharmacies, compounded goes through 503A or 503B compounding pharmacies.

Can a naturopathic doctor prescribe Zepbound? In most states, no. Only 26 states license naturopathic doctors, and most of those states restrict naturopathic formularies to exclude GLP-1 medications. Check your state's naturopathic practice act. In states where NDs can prescribe, they must hold DEA registration and state licensure.

Does the prescriber need to specialize in weight loss or obesity medicine? No. Board certification in obesity medicine (ABOM) or bariatric medicine is not required to prescribe Zepbound. Family medicine and internal medicine providers commonly prescribe GLP-1 medications. Specialty training matters more for complex cases than for straightforward weight loss.

Can a pharmacist prescribe Zepbound? In 13 states, clinical pharmacists can prescribe under collaborative practice agreements with physicians, but the formulary typically excludes weight-loss medications. In the remaining 37 states, pharmacists cannot prescribe Zepbound. Pharmacists can dispense Zepbound with a valid prescription from an authorized prescriber.

How do I verify that a telehealth provider is licensed in my state? Go to your state medical board website and use the license lookup tool. Search by the provider's name. The license must show as active and unrestricted. You can also verify DEA registration using the DEA practitioner lookup tool. If the platform won't provide the provider's full name and license number before your consultation, that's a red flag.

Can my gynecologist prescribe Zepbound? If your gynecologist is an MD or DO with an active license and DEA registration, they have the legal authority to prescribe Zepbound. Whether they will prescribe depends on whether weight-loss medication falls within their scope of practice. Most gynecologists refer to primary care or endocrinology for weight-loss medication.

What happens if my provider's license expires or is suspended? If your provider's license expires or is suspended, they lose prescribing authority immediately. You will need to transfer care to a different provider. Telehealth platforms monitor license status and will reassign you to a different provider if your current provider's license lapses. You can check license status yourself at your state medical board website.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. American Association of Nurse Practitioners. State Practice Environment. 2026.
3. Drug Enforcement Administration. Ryan Haight Online Pharmacy Consumer Protection Act. 2008.
4. National Council of State Boards of Nursing. Nurse Licensure Compact. 2025.
5. American Academy of Physician Assistants. State Supervision Requirements. 2026.
6. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2024.
7. Federation of State Medical Boards. State-Specific Requirements for Telemedicine. 2025.
8. American Board of Obesity Medicine. Certification Requirements. 2026.
9. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. Centers for Medicare and Medicaid Services. Telehealth Policy Changes After the COVID-19 Public Health Emergency. 2023.
11. National Association of Boards of Pharmacy. Compounding Pharmacy Regulation. 2025.
12. American College of Gastroenterology. Obesity Management Guidelines. 2022.
13. Obesity Medicine Association. Certified Obesity Care Provider Credential. 2026.
14. Eli Lilly and Company. Zepbound Prescribing Information. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.